Raghuram Selvaraju

Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. Analyst Raghuram Selvaraju reiterated a Neutral rating on the stock with a $17...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors can breathe a sigh of relief following the latest updates on the company’s Tampa facility, which was the subject of a Complete Response Letter Valeant received from the FDA earlier this month. IN the letter, the FDA pointed out Current...

Investors initially celebrated a mixed Q2 earnings report from Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to the tune of a 7 percent Tuesday-morning pop for the stock. However, that enthusiasm quickly evaporated as the reality of yet another guidance cut and an uncertain future started to sink in...

Inovio Pharmaceuticals Inc (NASDAQ: INO) announced Thursday morning it has commenced a Phase III clinical program (called REVEAL) to evaluate the efficacy of its DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus. Inovio's study will assess the efficacy...

Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...

Initiating coverage of Alimera Sciences Inc (NASDAQ: ALIM) at a Buy rating and a $4 price target, Rodman & Renshaw said it views the company's commercialized product lluvien, which is a fluocinolone acetonide intravitreal implant, is differentiated from other corticosteroid treatment options...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced last week it has been issued three new patents from the U.S. Patent and Trademark Office. The first patent relates to the manufacturing method for TRULANCE (plecanatide) and the other two relate to formulations and methods of using Trulance for...

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced the filing of the supplemental New Drug Application for Trulance (plecanatide) in constipation-predominant irritable bowel syndrome. Trulance’s approval in IBSC “should be a matter of routine,” Rodman & Renshaw’s...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY), a nano-cap pharmaceutical company that owns, markets and dispenses a portfolio of compounded therapeutic in several areas, reported improved quarterly results on a year-over-year basis. The company reported a loss of $0.44 per share in the fourth quarter...

Rodman & Renshaw reiterated its Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP), saying the company’s “best-in-class” safety profile should boost the commercial launch of Trulance for the treatment of chronic idiopathic constipation (CIC). Trulance “...

After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant irritable bowel syndrome (IBS-C). Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the...

Rodman & Renshaw’s Raghuram Selvaraju believes the top-line data announced by Synergy Pharmaceuticals Inc (NASDAQ: SGYP) from the first pivotal trial for plecanatide in constipation-predominant irritable bowel syndrome (IBS-C) positions the pipeline candidate as a “potentially best-...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its Q3 revenue and earnings short of expectations. The company’s sales could decline in 2017, partly due to competition from generic products, Rodman & Renshaw’s Raghuram Selvaraju said in a report. He downgraded the rating on...